{"ticker": {"uuid": "abad14e6-13b8-4a6a-b92c-e516cbbdc9aa", "symbol": "PLSE", "name": "Pulse Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)", "summary": "Pulse Biosciences announced inducement grants to three new employees consistent with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 51,000 stock options and 21,000 restricted stock units, were approved by the Compensation Committee and are intended to align the interests ", "url": "https://www.moomoo.com/news/flash/22803809/pulse-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635", "source_name": "Moomoo", "published_at": "2026-07-15T21:41:39", "published_display": "15 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences' Three New Employees Get $25.89 Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOTTVXYTRCdmFyZ3JrWWlfN1RUUnZiS0JvVDNRaDJPZ1c2NHZtYlpDbkxOTTFTSUFXdVctSDAtS0QtUkFIY2pXSWZ6SXRoXzQ0R0RsajZxbnBEM1ZvRXFoTlVJOUhabm9pdld2V1cxSXFiSFdIZjluNXdaYzJxWVdRb3VZSThjd1JkR0QwVnZaazZkRXI3dEdRTVhZT0luSmVYQ0d3S1g0aFNVU1NCSUJPV1JTZ19xRm93NXdPeWh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (PLSE) Price Events", "summary": "This article analyzes Pulse Biosciences Inc (PLSE) using AI models, highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including a long position strategy with a 72.3:1 risk-reward, a momentum breakout strategy", "url": "https://news.stocktradersdaily.com/news_release/22/Liquidity_Mapping_Around_PLSE_Price_Events_071326085802_1783947482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T08:41:47", "published_display": "13 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock stays tied to filings and financing", "summary": "Pulse Biosciences (PLSE) stock continues to be influenced by its Nasdaq listing, corporate disclosures, and clinical development work rather than commercial scale. As a life-sciences developer, investor focus remains on regulatory progress, financing, and program timing, with spe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulse-biosciences-stock-stays-tied-to-filings-and-financing/69681020", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:39:10", "published_display": "03 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative?", "summary": "Pulse Biosciences recently announced the redemption of remaining common stock warrants from its July 2024 rights offering, a move that could affect its capital structure and long-term positioning in cardiac ablation. This decision, alongside fresh analyst coverage and insider sha", "url": "https://www.sahmcapital.com/news/content/did-warrant-redemptions-just-reframe-pulse-biosciences-plse-cardiac-ablation-investment-narrative-2026-06-13", "source_name": "Sahm", "published_at": "2026-07-02T18:42:42", "published_display": "02 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This page provides financial data for Pulse Biosciences, Inc (NASDAQ: PLSE), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data-focused page from TradingView, indicating that the price-to-earnings forward value is displayed, a", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T04:35:39", "published_display": "02 Jul 2026 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLSE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pulse Biosciences, Inc (PLSE) stock, including analyst price targets and predictions for 2027. It details the company's recent stock performance, financial metrics like earnings and revenue, and key company information such as market capitaliz", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-01T18:10:31", "published_display": "01 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article focuses on the \"Price to sales forward\" metric for Pulse Biosciences, Inc (NASDAQ: PLSE). It provides a high-level overview of the company's financial data on the TradingView platform, indicating that the market is currently closed. The content is primarily a data pl", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:09:29", "published_display": "29 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "The article focuses on the \"Price to book forward\" financial metric for Pulse Biosciences, Inc. trading under the NASDAQ symbol PLSE. It appears to be a financial data presentation page from TradingView, indicating that the market for PLSE was closed with no trades at the time of", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T04:41:11", "published_display": "29 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This article from TradingView briefly presents the enterprise value to revenue forward for Pulse Biosciences, Inc. (FWB:6L8). The content appears to be a stub or a data placeholder, indicating no current trading activity for the specified market. It serves primarily as a navigati", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:41:11", "published_display": "28 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article focuses on the enterprise value to EBIT forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It appears to be a financial data snippet from TradingView, indicating a specific financial metric for the company. The content includes details like the stock market, company", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:39:33", "published_display": "28 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article provides an overview of Pulse Biosciences, Inc. (NASDAQ: PLSE) with a focus on its enterprise value to revenue forward. It indicates the stock market status on Nasdaq, noting that the market is closed with no trades. The article is primarily a financial snapshot from", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:11:01", "published_display": "28 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This page from TradingView displays financial information for Pulse Biosciences, Inc. (6L8) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-book ratio. The content also lists various TradingView products, community features, and company information.", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:11:01", "published_display": "28 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This article provides a brief overview of Pulse Biosciences, Inc. (FWB:6L8), focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Frankfurt Stock Exchange and its market is currently closed with no trades. The content specifically highli", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:09:58", "published_display": "28 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Institutional Confidence", "summary": "Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion recently increased by 30.37% quarter-over-quarter to 11.76%. The largest institutio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/sentiment", "source_name": "TradingKey", "published_at": "2026-06-27T05:39:13", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock hits 52-week high at $28.68", "summary": "Pulse Biosciences (PLSE) stock recently reached a 52-week high of $28.68, reflecting significant investor confidence with an 82.43% increase over the past year and over 100% year-to-date. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently ", "url": "https://www.investing.com/news/company-news/pulse-biosciences-stock-hits-52week-high-at-2868-93CH-4762938", "source_name": "Investing.com", "published_at": "2026-06-26T15:10:39", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE)", "summary": "This article provides an overview of Pulse Biosciences, Inc. (NASDAQ:PLSE) stock, including its current price, historical performance, and analyst forecasts. It details the company's financial actuals and estimates, such as earnings per share and revenue, and confirms that PLSE d", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:13", "published_display": "26 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com", "summary": "Pulse Biosciences Inc. (PLSE) stock reached a new 52-week high of $28.68, reflecting an 82.43% increase over the past year and over 100% year-to-date. This surge comes despite InvestingPro suggesting the stock may be overvalued, following positive Q1 2026 financial results, Canac", "url": "https://ca.investing.com/news/stock-market-news/pulse-biosciences-stock-hits-52week-high-at-2868-93CH-4709606", "source_name": "Investing.com Canada", "published_at": "2026-06-26T13:41:02", "published_display": "26 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8)", "summary": "This article provides financial actuals and analyst estimates for Pulse Biosciences, Inc. (DUS:6L8), including income statement, balance sheet, and cash flow data. It also covers commonly asked questions about the stock, such as its ticker, forecasts, historical prices, earnings ", "url": "https://www.tradingview.com/symbols/DUS-6L8/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:39", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6L8 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Pulse Biosciences, Inc. (6L8) stock on the Dusseldorf Stock Exchange. Based on three analyst ratings, the stock has a price target of 26.44 EUR, with a maximum estimate of 27.59 EUR and a minimum of 25.87 EUR. The company's rec", "url": "https://www.tradingview.com/symbols/DUS-6L8/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:03", "published_display": "25 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth", "summary": "The article discusses Pulse Biosciences (NASDAQ:PLSE) and evaluates its financial position regarding growth investments. It highlights that the company has more cash than debt and positive short-term assets exceeding liabilities, suggesting a strong balance sheet for future growt", "url": "https://www.moomoo.com/news/post/71972082/companies-like-pulse-biosciences-nasdaq-plse-are-in-a-position", "source_name": "Moomoo", "published_at": "2026-06-25T02:09:55", "published_display": "25 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulse Biosciences Inc (PLSE), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that PLSE's price momentum score is 7.45, with the stock trading between a resistance ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/technical", "source_name": "TradingKey", "published_at": "2026-06-24T08:10:47", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis", "summary": "Pulse Biosciences Inc (PLSE) has a current valuation score of 9.27, ranking 26th in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -23.31, reflecting a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios have not ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:07", "published_display": "23 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting?", "summary": "Pulse Biosciences (PLSE) saw its stock rise by 5.0% after being added to the S&P Healthcare Equipment Select Industry Index. This inclusion enhances visibility and comes alongside a strong financial health score and increased institutional ownership. However, the company still fa", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/pulse-biosciences-plse-is-up-50-after-joining-sp-healthcare", "source_name": "Simply Wall Street", "published_at": "2026-06-22T01:39:17", "published_display": "22 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (PLSE)", "summary": "This article analyzes potential momentum shifts in Pulse Biosciences Inc (PLSE), highlighting weak near-term sentiment that could precede changes in mid and long-term outlooks. It details AI-generated trading strategies for different risk profiles, including position, momentum, a", "url": "https://news.stocktradersdaily.com/news_release/34/Understanding_Momentum_Shifts_in_PLSE_062126063802_1782038282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T06:09:36", "published_display": "21 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Stock - weekly review and sector comparison", "summary": "This article provides a weekly review of Pulse Biosciences (PLSE) stock, focusing on its financial position and comparison within the early-stage medical device and aesthetic-technology sector. It highlights the company's focus on pulsed electric field-based medical technologies ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulse-biosciences-stock-weekly-review-and-sector-comparison/69583379", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T14:39:01", "published_display": "19 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Strengthens Executive Team", "summary": "Pulse Biosciences has strengthened its C-Suite by appointing Liane Teplitsky as Chief Operating Officer and expanding Dr. David Kenigsberg's role to full-time Chief Medical Officer. These strategic enhancements aim to accelerate the development and commercialization of the compan", "url": "https://www.mpo-mag.com/breaking-news/pulse-biosciences-strengthens-executive-team/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-18T15:09:20", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a timeline of dividend and stock split events for Pulse Biosciences Inc (PLSE). It states that the company has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The current stock price, market cap, and other bas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:33", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Pulse Biosciences Inc (PLSE). It details the company's revenue streams by business segment (Systems, Cycle units) and by geographic region (North America, Rest of World) for various fiscal periods. As of the stated update, all reporte", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:33", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Robert W. Duggan receives new PLSE stock option grants (NASDAQ: PLSE)", "summary": "Robert W. Duggan, a director and 10% owner of Pulse Biosciences (NASDAQ: PLSE), has received two new stock option grants totalling 42,495 shares as part of his equity compensation. These options have an exercise price of $26.89 per share and expire on June 11, 2036. The grants wi", "url": "https://www.stocktitan.net/sec-filings/PLSE/form-4-pulse-biosciences-inc-insider-trading-activity-8c5015d3f76a.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:33", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares", "summary": "Pulse Biosciences director Mahkam Zanganeh has been awarded two stock option grants totaling 44,504 shares (14,504 and 30,000 shares) at an exercise price of $26.89 per share, expiring on June 11, 2036. The 14,504-share option vests monthly over one year starting July 11, 2026, w", "url": "https://www.stocktitan.net/sec-filings/PLSE/form-4-pulse-biosciences-inc-insider-trading-activity-f057aa8bbb0e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:09:19", "published_display": "16 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences to Redeem Remaining Warrants From July 2024 Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-redeem-remaining-warrants-120334146.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:03:34+00:00", "published_display": "10 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Announces Planned Redemption of Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVzF2ZERrSGY3ejBzQmhwNVZZUzBTLW9rZU52SWxOMFdienhnMFNvQmNiNUpYWnM4V3JVS1BHbjNGYTlsb3FaNWE2c2k5ekpubzYxUjBFUUV6UnNkcEQ5ZzFDUWlKODBtUjJqUFFNUXEwZ1M5U1VkcG9MV1M2MnpvY2Y0Qk9RS3FVWUpWclNYR25RaG1aSjZGbjJnYklXZ0hMVnpQeXlqaUpXbnlYalJVazl0emNLTHZFRWx3Nw?oc=5", "source_name": "Business Wire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNYlZNTG05TzRIeHpVSk0zUVZkYWREYV9zSmxmZzNkUTRVT19mcEFiSTg5aFN6b2FrdVFJNFNtUlgyc29TR1FaTS13RDB5WGl3RXZNMXNUdzlfQlZhVnlQR0lqell3SjlSWE5ZczBGM2NDN3hDUzI1dlFuU3hUOTkyU1dKaTgwWWlTQlM0OFlVRTVZWXlQVmw3U2lYREs5ZFZuc1E?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences management to speak at Goldman Sachs healthcare conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMlduQ2hiZjhxMTNpdG05WTFSWW91cGx2WXZxZ1NKRnZSS1YtME5UelcyZUFZUGc1U0xTNmlfYlUtLXNUWnNlbFR1N2xpQ2Jhc2pWTmxfOW1fc0k4TEFjd1ZyT0xNNEloZjdTSmlFcFFJemFncGpFcGxiRFdrNE9haHdIeGFJVFk3akpOY3dpYmxCNzVDT0M4QWVwM2h0RWI1czg5dGxVd2o4Qms3Um4zVGVvaHg4MjdGZXFmc2gzN3g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNYmQwU0FSMmh4QzhNRzZqNEwwMExpS2U2cGhBMlFPeHlBVUM4TmMyaldETDZBdjJTdVJFeWtpc21iNHVBSTdQM190Qm1UMmJHSGp1NXdycl82LTZVdFhuQkdBSkoxd3ZJSEdpcEFDY1ZURWpsbjB4SkRQOGo5YTh0YjRGTmRLdTJWbkFqWUR6Q3VRRzhqRXNPYU5FR1o?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.", "summary": "", "url": "https://finance.yahoo.com/m/974b2a31-37ef-3a09-9cab-29b03631b334/pulse-biosciences-ceo-bought.html", "source_name": "Motley Fool", "published_at": "2026-05-17T15:02:01+00:00", "published_display": "17 May 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-insider-bought-shares-081642469.html", "source_name": "MT Newswires", "published_at": "2026-05-12T08:16:42+00:00", "published_display": "12 May 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Insider Bought Shares Worth $295,350, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-insider-bought-shares-081619969.html", "source_name": "MT Newswires", "published_at": "2026-05-12T08:16:19+00:00", "published_display": "12 May 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNWDZUdWQ0UlltTUpCMjdTWTRsTXhxY04xa2VXTlU1UGdnRENLdzFmeTFodFduelIyVzFvaHRsRkhJbl9uLWxJS2w5YkZlSmtFYzRWTnBmaW5qLTZkcDRYdjBCb1lOMERHZW45RkZ4a0ZYZkJDbXRJa0ZPRVpBXzBONUY5V3NpS3JoXzNhbGFmMTBBcHlXaVNXTmJhdmgzeVlhUkpSZDE4aUFNdWZPMml2Z29xa0NrUmRtQzlpelR0WGdNY3pZQmp1dzhGYkdleHFVcTdhamlJUjRtVUhLRFJB?oc=5", "source_name": "Business Wire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSDJPWWxWY01jODBoX1kwc0d1SHRNS3JuR1l2NEpKczJ1Mi1QY3pFZWlidW8yQjdoQU5YQUxFQjFMa2U2UlZfeTFocmFIV08yM3FBaTR0eTNVMzNXX0dtbEhZaF9mRkFHMmxaNE1KcnNaNnhKOHA1eUVKTG9aY3lRcjNrOWs5cjc0R3ZaRGdtbk1BRUZlSzV0Mm9VR0JjbUFxUHJHbjBqNmZ2eWVLZ3Zv?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPM1pEM1pBempiVUF1ZkRIWTJibkJqZnp4UWlSZ1I4ZHh3NXkwVDZJQUdNT1d1M2pVVXhXX21obXBwNzkycHRSalhWZ1U0MnNYZzl2SUhhMHYtM2EyaGI5LWNPcWpjSWxNeXpCMXNhV0QyX0xrSldDRU9kU1dqUnFOWHdReUdTV1djdUozVk04WWlISmEzZExWYVczbmU4dzV6bHc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOU2NDNjdDcU54bjlQaEF6U09JZ2lZdUcxV29VT0Z2MEdlNXRhcjc5WDgyZ0xEOFNhRWxRV0JZTk5wZHU2Um1WQ2QweDhpVmtrbFh3WV8wRkNYWmxIMTB6dHlESnBvanpwQXVMTXZfb0hBVWoxcXJ1bDJ5QnJLUERoRVVEeUJMV2tDM0FmdXM3S0lRek03SzJJWEJpZ2d5Y3pNTTBlUWpJVzBNMWJydGo3NmNXOHRFaWNKY3VkSm9mNEppZVZ5MU1OODdMdVNwazN6NjdMbDg4WQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTmlFRjhSbHZkaUM0SXFULTJHX2g4VGNkcDZlNlFXQWVCcERPNjdyaG5LUGhEc1ctUEpxbXp1bXE4UWxUdGM3czZYS0RaUW9OZVB3bzhIVDlYLXJFTTNsbVp2REd5ZW5iWkJPbG03cnhSLU9YRXVsdGlIOGVCdEZ5LTVFc25rdDdLT05iY0R2NGlEeldJdEtnS3lZdUZxZkZtbGNKSXhR?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPd3JrUHJBdy1fdlJlUm1GV2pBWVJxZXYtYy1iSm0ySmhFUU5VSjRxaF9SQ2ZyWkZISmlIZ2N2YWlVcEZwRE44OVJuZ3dpQUsyNEFTakpXRVBnN0FTTWpLQXFmWmFaVnBYVy1ZZUZ1ZHdyVWRrM0JXNU5tNEEwdURVNTdxVHFnSmx5dHR6Sk11M1ZlLXdhMFhZWnBRX1ZSZHJacmU0MEZvV3M?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences to Host Analyst Event on April 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPakZKcXc0UGFuTFdxY19iRGRhd0M5Y3JqcnVlaThRaXM0WVg0Ry1JUEk5eTl0d0NGOVZVUlMtanhFbUltalFGU3RodFQ5bHR2Z0xTT3NTeEs4em0tQzVDODNIUTR2Mk1hdDE2ZDZOMk9YMUdaYno5cEJycHN1WHlzdWVwazF6eWZ4VmsxZGJBX3BpZFpzQVI4V0E5bnZMcUtDWEFabHkzTnBMSnpjY2hjdFcxZw?oc=5", "source_name": "Business Wire", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYkxRUFdpdlFPVU5Mb2VwRHRuNVpGYjJ4cFdvckxzQVpmNjNuYklBbzVtN0liamVQWGpWRHhsMS1YVnJlSFFJNDdjdTRnYXltQmoybVZJSU1mNGw5dktHM2xEVjVUM0JKSjh3LXBOckpQYjRBbU00aUx6YVpTQl9Vc0xtNUpzU09QZjdzSGMtVDhoTGJYYTctWTQxMFpPZ1BqTkUzTnFpQy0xeTZHaHEwckt1U0Q1UWlSNEhtZExBR0tIaWxlQnFXTnBjOG5iTlY4NFJfNWlJSHJ1c1FFd3VwdU5pbHlPdw?oc=5", "source_name": "Trefis", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBPYkZ3c2JKRTktYS0xcDN0S1ZlcE94VTF6OTV1REZVN0hXQXlrZ2ROM1FXaXdocTV5VFdGdld6VjNDaGRKWDl6WkdZZlVaZGtWRVI0elphamtrRjl2Z2ZPSjB3dldxTjlSQkQyYTFIWmN0bUZKeDQxVW5GV3Fndw?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOTnpQTmQ4d0Q5ckdRMUduM0R3OFVKQWNBS1RDSGo4eDVDb3dHNkxBSGFEclNJMzVpcDlVRVpFckR4ZElTQmJ3aHVKcXlDbXZvVnh5eTh2MnNkRG11WC13M2hHV2YtYVZhaElzWDFUb1pndHFLLS1XOVlYZ251WVIyb3BXUjhWVUMtN2NxYndzdXNiY29IYXpZYWxOVU9DNXU0RWZmOWVTS190QzFhNGNjaHFwMWt4Y2RiZ0hTQkdQeENscWl5TFlBV01Hd09JR05NUUN6S0poU0NUOUpIV3cyRmVYaTIyNnpHNmxySHlTdDVYOXluU1l6TXJrZFVfQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, MD Anderson, launch study of novel ablation technology for thyroid cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcW54aDRuVW5kaUo3SGFER3FfWHE4OHhheWlJLW9vMlpsSmJraDRuNWxkeUNTS3Jfc0NOejZEZkgwVXdMRUJ1bzJrcWprVmxJbTlya0hVdHlOc21UUGZwRWpsM3FSRkNRSlEyOU8zTXdfRUl6aFhGN3FNc3VLbjVxSUFzYm9vQ2VTMFgwOUVoQTNaWkxneWhGTm55MnZHcE45UmlHa3FyRlRXX0tQWmUyY2J3aDlBYUwydGFGV2hwY1Vta255cmk0?oc=5", "source_name": "Medical Economics", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)", "summary": "Pulse Biosciences announced inducement grants to three new employees consistent with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 51,000 stock options and 21,000 restricted stock units, were approved by the Compensation Committee and are intended to align the interests ", "url": "https://www.moomoo.com/news/flash/22803809/pulse-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635", "source_name": "Moomoo", "published_at": "2026-07-15T21:41:39", "published_display": "15 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences' Three New Employees Get $25.89 Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOTTVXYTRCdmFyZ3JrWWlfN1RUUnZiS0JvVDNRaDJPZ1c2NHZtYlpDbkxOTTFTSUFXdVctSDAtS0QtUkFIY2pXSWZ6SXRoXzQ0R0RsajZxbnBEM1ZvRXFoTlVJOUhabm9pdld2V1cxSXFiSFdIZjluNXdaYzJxWVdRb3VZSThjd1JkR0QwVnZaazZkRXI3dEdRTVhZT0luSmVYQ0d3S1g0aFNVU1NCSUJPV1JTZ19xRm93NXdPeWh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (PLSE) Price Events", "summary": "This article analyzes Pulse Biosciences Inc (PLSE) using AI models, highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including a long position strategy with a 72.3:1 risk-reward, a momentum breakout strategy", "url": "https://news.stocktradersdaily.com/news_release/22/Liquidity_Mapping_Around_PLSE_Price_Events_071326085802_1783947482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T08:41:47", "published_display": "13 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock stays tied to filings and financing", "summary": "Pulse Biosciences (PLSE) stock continues to be influenced by its Nasdaq listing, corporate disclosures, and clinical development work rather than commercial scale. As a life-sciences developer, investor focus remains on regulatory progress, financing, and program timing, with spe", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulse-biosciences-stock-stays-tied-to-filings-and-financing/69681020", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:39:10", "published_display": "03 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative?", "summary": "Pulse Biosciences recently announced the redemption of remaining common stock warrants from its July 2024 rights offering, a move that could affect its capital structure and long-term positioning in cardiac ablation. This decision, alongside fresh analyst coverage and insider sha", "url": "https://www.sahmcapital.com/news/content/did-warrant-redemptions-just-reframe-pulse-biosciences-plse-cardiac-ablation-investment-narrative-2026-06-13", "source_name": "Sahm", "published_at": "2026-07-02T18:42:42", "published_display": "02 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This page provides financial data for Pulse Biosciences, Inc (NASDAQ: PLSE), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data-focused page from TradingView, indicating that the price-to-earnings forward value is displayed, a", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T04:35:39", "published_display": "02 Jul 2026 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLSE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Pulse Biosciences, Inc (PLSE) stock, including analyst price targets and predictions for 2027. It details the company's recent stock performance, financial metrics like earnings and revenue, and key company information such as market capitaliz", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-07-01T18:10:31", "published_display": "01 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article focuses on the \"Price to sales forward\" metric for Pulse Biosciences, Inc (NASDAQ: PLSE). It provides a high-level overview of the company's financial data on the TradingView platform, indicating that the market is currently closed. The content is primarily a data pl", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:09:29", "published_display": "29 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "The article focuses on the \"Price to book forward\" financial metric for Pulse Biosciences, Inc. trading under the NASDAQ symbol PLSE. It appears to be a financial data presentation page from TradingView, indicating that the market for PLSE was closed with no trades at the time of", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T04:41:11", "published_display": "29 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This article from TradingView briefly presents the enterprise value to revenue forward for Pulse Biosciences, Inc. (FWB:6L8). The content appears to be a stub or a data placeholder, indicating no current trading activity for the specified market. It serves primarily as a navigati", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:41:11", "published_display": "28 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article focuses on the enterprise value to EBIT forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It appears to be a financial data snippet from TradingView, indicating a specific financial metric for the company. The content includes details like the stock market, company", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:39:33", "published_display": "28 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pulse Biosciences, Inc \u2013 NASDAQ:PLSE", "summary": "This article provides an overview of Pulse Biosciences, Inc. (NASDAQ: PLSE) with a focus on its enterprise value to revenue forward. It indicates the stock market status on Nasdaq, noting that the market is closed with no trades. The article is primarily a financial snapshot from", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:11:01", "published_display": "28 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This page from TradingView displays financial information for Pulse Biosciences, Inc. (6L8) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-book ratio. The content also lists various TradingView products, community features, and company information.", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:11:01", "published_display": "28 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulse Biosciences, Inc. \u2013 FWB:6L8", "summary": "This article provides a brief overview of Pulse Biosciences, Inc. (FWB:6L8), focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Frankfurt Stock Exchange and its market is currently closed with no trades. The content specifically highli", "url": "https://www.tradingview.com/symbols/FWB-6L8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:09:58", "published_display": "28 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Institutional Confidence", "summary": "Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion recently increased by 30.37% quarter-over-quarter to 11.76%. The largest institutio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/sentiment", "source_name": "TradingKey", "published_at": "2026-06-27T05:39:13", "published_display": "27 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock hits 52-week high at $28.68", "summary": "Pulse Biosciences (PLSE) stock recently reached a 52-week high of $28.68, reflecting significant investor confidence with an 82.43% increase over the past year and over 100% year-to-date. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently ", "url": "https://www.investing.com/news/company-news/pulse-biosciences-stock-hits-52week-high-at-2868-93CH-4762938", "source_name": "Investing.com", "published_at": "2026-06-26T15:10:39", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE)", "summary": "This article provides an overview of Pulse Biosciences, Inc. (NASDAQ:PLSE) stock, including its current price, historical performance, and analyst forecasts. It details the company's financial actuals and estimates, such as earnings per share and revenue, and confirms that PLSE d", "url": "https://www.tradingview.com/symbols/NASDAQ-PLSE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:13", "published_display": "26 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com", "summary": "Pulse Biosciences Inc. (PLSE) stock reached a new 52-week high of $28.68, reflecting an 82.43% increase over the past year and over 100% year-to-date. This surge comes despite InvestingPro suggesting the stock may be overvalued, following positive Q1 2026 financial results, Canac", "url": "https://ca.investing.com/news/stock-market-news/pulse-biosciences-stock-hits-52week-high-at-2868-93CH-4709606", "source_name": "Investing.com Canada", "published_at": "2026-06-26T13:41:02", "published_display": "26 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8)", "summary": "This article provides financial actuals and analyst estimates for Pulse Biosciences, Inc. (DUS:6L8), including income statement, balance sheet, and cash flow data. It also covers commonly asked questions about the stock, such as its ticker, forecasts, historical prices, earnings ", "url": "https://www.tradingview.com/symbols/DUS-6L8/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:39", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6L8 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Pulse Biosciences, Inc. (6L8) stock on the Dusseldorf Stock Exchange. Based on three analyst ratings, the stock has a price target of 26.44 EUR, with a maximum estimate of 27.59 EUR and a minimum of 25.87 EUR. The company's rec", "url": "https://www.tradingview.com/symbols/DUS-6L8/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:03", "published_display": "25 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth", "summary": "The article discusses Pulse Biosciences (NASDAQ:PLSE) and evaluates its financial position regarding growth investments. It highlights that the company has more cash than debt and positive short-term assets exceeding liabilities, suggesting a strong balance sheet for future growt", "url": "https://www.moomoo.com/news/post/71972082/companies-like-pulse-biosciences-nasdaq-plse-are-in-a-position", "source_name": "Moomoo", "published_at": "2026-06-25T02:09:55", "published_display": "25 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulse Biosciences Inc (PLSE), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that PLSE's price momentum score is 7.45, with the stock trading between a resistance ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/technical", "source_name": "TradingKey", "published_at": "2026-06-24T08:10:47", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis", "summary": "Pulse Biosciences Inc (PLSE) has a current valuation score of 9.27, ranking 26th in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -23.31, reflecting a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios have not ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:07", "published_display": "23 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting?", "summary": "Pulse Biosciences (PLSE) saw its stock rise by 5.0% after being added to the S&P Healthcare Equipment Select Industry Index. This inclusion enhances visibility and comes alongside a strong financial health score and increased institutional ownership. However, the company still fa", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/pulse-biosciences-plse-is-up-50-after-joining-sp-healthcare", "source_name": "Simply Wall Street", "published_at": "2026-06-22T01:39:17", "published_display": "22 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (PLSE)", "summary": "This article analyzes potential momentum shifts in Pulse Biosciences Inc (PLSE), highlighting weak near-term sentiment that could precede changes in mid and long-term outlooks. It details AI-generated trading strategies for different risk profiles, including position, momentum, a", "url": "https://news.stocktradersdaily.com/news_release/34/Understanding_Momentum_Shifts_in_PLSE_062126063802_1782038282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T06:09:36", "published_display": "21 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Stock - weekly review and sector comparison", "summary": "This article provides a weekly review of Pulse Biosciences (PLSE) stock, focusing on its financial position and comparison within the early-stage medical device and aesthetic-technology sector. It highlights the company's focus on pulsed electric field-based medical technologies ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulse-biosciences-stock-weekly-review-and-sector-comparison/69583379", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T14:39:01", "published_display": "19 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Strengthens Executive Team", "summary": "Pulse Biosciences has strengthened its C-Suite by appointing Liane Teplitsky as Chief Operating Officer and expanding Dr. David Kenigsberg's role to full-time Chief Medical Officer. These strategic enhancements aim to accelerate the development and commercialization of the compan", "url": "https://www.mpo-mag.com/breaking-news/pulse-biosciences-strengthens-executive-team/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-18T15:09:20", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a timeline of dividend and stock split events for Pulse Biosciences Inc (PLSE). It states that the company has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The current stock price, market cap, and other bas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:33", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Pulse Biosciences Inc (PLSE). It details the company's revenue streams by business segment (Systems, Cycle units) and by geographic region (North America, Rest of World) for various fiscal periods. As of the stated update, all reporte", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plse/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T16:39:33", "published_display": "17 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Robert W. Duggan receives new PLSE stock option grants (NASDAQ: PLSE)", "summary": "Robert W. Duggan, a director and 10% owner of Pulse Biosciences (NASDAQ: PLSE), has received two new stock option grants totalling 42,495 shares as part of his equity compensation. These options have an exercise price of $26.89 per share and expire on June 11, 2036. The grants wi", "url": "https://www.stocktitan.net/sec-filings/PLSE/form-4-pulse-biosciences-inc-insider-trading-activity-8c5015d3f76a.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:33", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares", "summary": "Pulse Biosciences director Mahkam Zanganeh has been awarded two stock option grants totaling 44,504 shares (14,504 and 30,000 shares) at an exercise price of $26.89 per share, expiring on June 11, 2036. The 14,504-share option vests monthly over one year starting July 11, 2026, w", "url": "https://www.stocktitan.net/sec-filings/PLSE/form-4-pulse-biosciences-inc-insider-trading-activity-f057aa8bbb0e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:09:19", "published_display": "16 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences to Redeem Remaining Warrants From July 2024 Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-redeem-remaining-warrants-120334146.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:03:34+00:00", "published_display": "10 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc. Announces Planned Redemption of Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVzF2ZERrSGY3ejBzQmhwNVZZUzBTLW9rZU52SWxOMFdienhnMFNvQmNiNUpYWnM4V3JVS1BHbjNGYTlsb3FaNWE2c2k5ekpubzYxUjBFUUV6UnNkcEQ5ZzFDUWlKODBtUjJqUFFNUXEwZ1M5U1VkcG9MV1M2MnpvY2Y0Qk9RS3FVWUpWclNYR25RaG1aSjZGbjJnYklXZ0hMVnpQeXlqaUpXbnlYalJVazl0emNLTHZFRWx3Nw?oc=5", "source_name": "Business Wire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNYlZNTG05TzRIeHpVSk0zUVZkYWREYV9zSmxmZzNkUTRVT19mcEFiSTg5aFN6b2FrdVFJNFNtUlgyc29TR1FaTS13RDB5WGl3RXZNMXNUdzlfQlZhVnlQR0lqell3SjlSWE5ZczBGM2NDN3hDUzI1dlFuU3hUOTkyU1dKaTgwWWlTQlM0OFlVRTVZWXlQVmw3U2lYREs5ZFZuc1E?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQLVdMRmRVRThGbFN5UHE5aWFPRDVoNFhZdld0LWp4WFdObnpWMnlYMjRLbENVcUxaRjdEZVdkQ3Z5ZUo0NEs2dDNOZXpYNHBvc29oUVN2SFdLRFZZMXU3YXJVRlNzd05SS1l0RDNtdHJxNTJKRmozUHFDeWQ3RjBoYUs2ZEVicW04bDdROUVlVDBQVG51cE00MWp2TTRxOEJheEhaaEs0UjFsZk9HWDNuVWRESzJXMUFNUTR0dmZTeFctdG9ESXhJQWR3b2NvNVdwZ1FiatIB2gFBVV95cUxORTFlRkNtRE9YTE10Vko2S05UMk9hMFpoa3NRem5LelEzQWoybjBoMDQ2eTdBeTRLYVpwZERaaFpqRW5sMEpXeGRqSVl2RkItUFFKblJ1WU9NNWRzb2NiTjliSVNYRnI3VDNZbF9BN1NJSFZQaDZWMFJQbmluTFNmS1d5VmhqOERyeTFjWmV5R3RjeEEzbUlkNlM5N2pGS0RhV01SSnlKMHM0SENpTUREWUlMNVpuUWNma1AwRGpuUHd2VDdtM2lsOXhOb0xySkRoUS1kYndUQkY2dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences management to speak at Goldman Sachs healthcare conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMlduQ2hiZjhxMTNpdG05WTFSWW91cGx2WXZxZ1NKRnZSS1YtME5UelcyZUFZUGc1U0xTNmlfYlUtLXNUWnNlbFR1N2xpQ2Jhc2pWTmxfOW1fc0k4TEFjd1ZyT0xNNEloZjdTSmlFcFFJemFncGpFcGxiRFdrNE9haHdIeGFJVFk3akpOY3dpYmxCNzVDT0M4QWVwM2h0RWI1czg5dGxVd2o4Qms3Um4zVGVvaHg4MjdGZXFmc2gzN3g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNYmQwU0FSMmh4QzhNRzZqNEwwMExpS2U2cGhBMlFPeHlBVUM4TmMyaldETDZBdjJTdVJFeWtpc21iNHVBSTdQM190Qm1UMmJHSGp1NXdycl82LTZVdFhuQkdBSkoxd3ZJSEdpcEFDY1ZURWpsbjB4SkRQOGo5YTh0YjRGTmRLdTJWbkFqWUR6Q3VRRzhqRXNPYU5FR1o?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.", "summary": "", "url": "https://finance.yahoo.com/m/974b2a31-37ef-3a09-9cab-29b03631b334/pulse-biosciences-ceo-bought.html", "source_name": "Motley Fool", "published_at": "2026-05-17T15:02:01+00:00", "published_display": "17 May 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-insider-bought-shares-081642469.html", "source_name": "MT Newswires", "published_at": "2026-05-12T08:16:42+00:00", "published_display": "12 May 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Insider Bought Shares Worth $295,350, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulse-biosciences-insider-bought-shares-081619969.html", "source_name": "MT Newswires", "published_at": "2026-05-12T08:16:19+00:00", "published_display": "12 May 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNWDZUdWQ0UlltTUpCMjdTWTRsTXhxY04xa2VXTlU1UGdnRENLdzFmeTFodFduelIyVzFvaHRsRkhJbl9uLWxJS2w5YkZlSmtFYzRWTnBmaW5qLTZkcDRYdjBCb1lOMERHZW45RkZ4a0ZYZkJDbXRJa0ZPRVpBXzBONUY5V3NpS3JoXzNhbGFmMTBBcHlXaVNXTmJhdmgzeVlhUkpSZDE4aUFNdWZPMml2Z29xa0NrUmRtQzlpelR0WGdNY3pZQmp1dzhGYkdleHFVcTdhamlJUjRtVUhLRFJB?oc=5", "source_name": "Business Wire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSDJPWWxWY01jODBoX1kwc0d1SHRNS3JuR1l2NEpKczJ1Mi1QY3pFZWlidW8yQjdoQU5YQUxFQjFMa2U2UlZfeTFocmFIV08yM3FBaTR0eTNVMzNXX0dtbEhZaF9mRkFHMmxaNE1KcnNaNnhKOHA1eUVKTG9aY3lRcjNrOWs5cjc0R3ZaRGdtbk1BRUZlSzV0Mm9VR0JjbUFxUHJHbjBqNmZ2eWVLZ3Zv?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPM1pEM1pBempiVUF1ZkRIWTJibkJqZnp4UWlSZ1I4ZHh3NXkwVDZJQUdNT1d1M2pVVXhXX21obXBwNzkycHRSalhWZ1U0MnNYZzl2SUhhMHYtM2EyaGI5LWNPcWpjSWxNeXpCMXNhV0QyX0xrSldDRU9kU1dqUnFOWHdReUdTV1djdUozVk04WWlISmEzZExWYVczbmU4dzV6bHc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOU2NDNjdDcU54bjlQaEF6U09JZ2lZdUcxV29VT0Z2MEdlNXRhcjc5WDgyZ0xEOFNhRWxRV0JZTk5wZHU2Um1WQ2QweDhpVmtrbFh3WV8wRkNYWmxIMTB6dHlESnBvanpwQXVMTXZfb0hBVWoxcXJ1bDJ5QnJLUERoRVVEeUJMV2tDM0FmdXM3S0lRek03SzJJWEJpZ2d5Y3pNTTBlUWpJVzBNMWJydGo3NmNXOHRFaWNKY3VkSm9mNEppZVZ5MU1OODdMdVNwazN6NjdMbDg4WQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTmlFRjhSbHZkaUM0SXFULTJHX2g4VGNkcDZlNlFXQWVCcERPNjdyaG5LUGhEc1ctUEpxbXp1bXE4UWxUdGM3czZYS0RaUW9OZVB3bzhIVDlYLXJFTTNsbVp2REd5ZW5iWkJPbG03cnhSLU9YRXVsdGlIOGVCdEZ5LTVFc25rdDdLT05iY0R2NGlEeldJdEtnS3lZdUZxZkZtbGNKSXhR?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPd3JrUHJBdy1fdlJlUm1GV2pBWVJxZXYtYy1iSm0ySmhFUU5VSjRxaF9SQ2ZyWkZISmlIZ2N2YWlVcEZwRE44OVJuZ3dpQUsyNEFTakpXRVBnN0FTTWpLQXFmWmFaVnBYVy1ZZUZ1ZHdyVWRrM0JXNU5tNEEwdURVNTdxVHFnSmx5dHR6Sk11M1ZlLXdhMFhZWnBRX1ZSZHJacmU0MEZvV3M?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences to Host Analyst Event on April 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPakZKcXc0UGFuTFdxY19iRGRhd0M5Y3JqcnVlaThRaXM0WVg0Ry1JUEk5eTl0d0NGOVZVUlMtanhFbUltalFGU3RodFQ5bHR2Z0xTT3NTeEs4em0tQzVDODNIUTR2Mk1hdDE2ZDZOMk9YMUdaYno5cEJycHN1WHlzdWVwazF6eWZ4VmsxZGJBX3BpZFpzQVI4V0E5bnZMcUtDWEFabHkzTnBMSnpjY2hjdFcxZw?oc=5", "source_name": "Business Wire", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYkxRUFdpdlFPVU5Mb2VwRHRuNVpGYjJ4cFdvckxzQVpmNjNuYklBbzVtN0liamVQWGpWRHhsMS1YVnJlSFFJNDdjdTRnYXltQmoybVZJSU1mNGw5dktHM2xEVjVUM0JKSjh3LXBOckpQYjRBbU00aUx6YVpTQl9Vc0xtNUpzU09QZjdzSGMtVDhoTGJYYTctWTQxMFpPZ1BqTkUzTnFpQy0xeTZHaHEwckt1U0Q1UWlSNEhtZExBR0tIaWxlQnFXTnBjOG5iTlY4NFJfNWlJSHJ1c1FFd3VwdU5pbHlPdw?oc=5", "source_name": "Trefis", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBPYkZ3c2JKRTktYS0xcDN0S1ZlcE94VTF6OTV1REZVN0hXQXlrZ2ROM1FXaXdocTV5VFdGdld6VjNDaGRKWDl6WkdZZlVaZGtWRVI0elphamtrRjl2Z2ZPSjB3dldxTjlSQkQyYTFIWmN0bUZKeDQxVW5GV3Fndw?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOTnpQTmQ4d0Q5ckdRMUduM0R3OFVKQWNBS1RDSGo4eDVDb3dHNkxBSGFEclNJMzVpcDlVRVpFckR4ZElTQmJ3aHVKcXlDbXZvVnh5eTh2MnNkRG11WC13M2hHV2YtYVZhaElzWDFUb1pndHFLLS1XOVlYZ251WVIyb3BXUjhWVUMtN2NxYndzdXNiY29IYXpZYWxOVU9DNXU0RWZmOWVTS190QzFhNGNjaHFwMWt4Y2RiZ0hTQkdQeENscWl5TFlBV01Hd09JR05NUUN6S0poU0NUOUpIV3cyRmVYaTIyNnpHNmxySHlTdDVYOXluU1l6TXJrZFVfQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulse Biosciences, MD Anderson, launch study of novel ablation technology for thyroid cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcW54aDRuVW5kaUo3SGFER3FfWHE4OHhheWlJLW9vMlpsSmJraDRuNWxkeUNTS3Jfc0NOejZEZkgwVXdMRUJ1bzJrcWprVmxJbTlya0hVdHlOc21UUGZwRWpsM3FSRkNRSlEyOU8zTXdfRUl6aFhGN3FNc3VLbjVxSUFzYm9vQ2VTMFgwOUVoQTNaWkxneWhGTm55MnZHcE45UmlHa3FyRlRXX0tQWmUyY2J3aDlBYUwydGFGV2hwY1Vta255cmk0?oc=5", "source_name": "Medical Economics", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 89, "total_relevant": 52, "sentiment_summary": {"positive": 12, "negative": 2, "neutral": 38, "score": 54, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 26.29, "latest_week": "2026-07-10", "one_week_move": -10.0, "four_week_move": 7.9, "twelve_week_move": 12.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.975049, "market_dynamics_buy_signal": false, "relative_strength": 21.228975, "fair_value_gap": 76.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.5866, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.0% over one week, +7.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "Business Wire", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-10.0% over one week, +7.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)"}], "updated_at": "2026-07-17T06:44:40.778807+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}